Anastrozole: Arimidex® 1st line Metastatic Breast Cancer

• Approved: September, 2000

• Trials: 2 randomized Phase 3

• Comparator: Tamoxifen

• Sample size: 1021 patients in all trials

• 1° Endpoints: Response rate, TTP

• Designed to show non-inferiority

Previous slide

Next slide

Back to first slide

View graphic version